How NeuroPace, Inc. stacks up

NPCE · against 1,327 other Healthcare companies

Overall

29/ 100

Near the bottom of its peers.

Ranked #1,135 of 1,328 · scores higher than 13% of peers

Bars: peers in each 10-point band of the overall score

131 peers with an overall score of 20–29, including NPCE · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#953 of 1,337Score 8 / 100 · beats 8%Growth#226 of 1,217Score 81 / 100 · beats 81%Profitability#1,009 of 1,336Score 24 / 100 · beats 24%Risk#1,308 of 1,373Higher relative risk · safety 5 · beats 5%

Ranking by overall score

Top 5 and the companies ranked around NPCE

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	BB Biotech AGBBZA.DE · Europe	3.1B EUR (≈$3.4B)	100		100	100	0 / 2
2	Arbutus Biopharma CorporationABUS · US-listed	595M USD	97	96	98	99	0 / 2
2	Q32 Bio Inc.QTTB · US-listed	261M USD	97	93	—	98	0 / 2
4	Lakefront Biotherapeutics NVLKFT · US-listed	2.1B USD	96	96	99	93	0 / 2
4	Zealand Pharma A/SZEAL.CO · Europe	15.6B DKK (≈$2.3B)	96	96	99	96	0 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

⋯
1,135	Beijing Hotgen Biotech Co., Ltd.688068.SS · China	6.0B CNY (≈$841M)	29	0	4	23	0 / 2